[{"address1": "121 Richmond Street West", "address2": "Penthouse Suite, 1300", "city": "Toronto", "state": "ON", "zip": "M5H2K1", "country": "Canada", "phone": "416 346 7764", "website": "https://www.psyencebiomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jody  Aufrichtig", "age": 51, "title": "Co-Founder, Executive Chairman & CEO", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 216667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warwick Ron Corden-Lloyd", "age": 45, "title": "CFO & Director", "yearBorn": 1980, "fiscalYear": 2025, "totalPay": 195000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil  Maresky M.D.", "age": 61, "title": "Global Head of Clinical Development", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 390000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Taryn  Vos", "title": "General Counsel", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.6161, "open": 2.64, "dayLow": 2.48, "dayHigh": 2.64, "regularMarketPreviousClose": 2.6161, "regularMarketOpen": 2.64, "regularMarketDayLow": 2.48, "regularMarketDayHigh": 2.64, "payoutRatio": 0.0, "beta": 0.315, "volume": 38180, "regularMarketVolume": 38180, "averageVolume": 160875, "averageVolume10days": 659710, "averageDailyVolume10Day": 659710, "bid": 2.34, "ask": 2.59, "bidSize": 1, "askSize": 1, "marketCap": 2555445, "fiftyTwoWeekLow": 2.48, "fiftyTwoWeekHigh": 468.35938, "allTimeHigh": 341015.62, "allTimeLow": 2.535, "fiftyDayAverage": 28.497705, "twoHundredDayAverage": 125.18927, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -6401165, "profitMargins": 0.0, "floatShares": 299169, "sharesOutstanding": 1022177, "sharesShort": 23267, "sharesShortPriorMonth": 18193, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0228, "heldPercentInsiders": 0.09986, "heldPercentInstitutions": 0.02802, "shortRatio": 0.31, "shortPercentOfFloat": 0.0228, "impliedSharesOutstanding": 1022178, "bookValue": 39.619, "priceToBook": 0.06310104, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -3941597, "trailingEps": -389.98, "lastSplitFactor": "16:100", "lastSplitDate": 1769990400, "enterpriseToEbitda": 1.544, "52WeekChange": -0.9927294, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 2.5, "recommendationKey": "none", "totalCash": 7149985, "totalCashPerShare": 23.871, "ebitda": -4145455, "totalDebt": 0, "quickRatio": 7.766, "currentRatio": 8.09, "returnOnAssets": -0.34442002, "returnOnEquity": -0.74286, "freeCashflow": -4006023, "operatingCashflow": -4247508, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PBM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": 22.399998, "postMarketPrice": 3.06, "postMarketChange": 0.55999994, "regularMarketChange": -0.11610007, "regularMarketDayRange": "2.48 - 2.64", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 160875, "fiftyDayAverageChange": -25.997705, "fiftyDayAverageChangePercent": -0.91227365, "twoHundredDayAverageChange": -122.68927, "twoHundredDayAverageChangePercent": -0.98003024, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639146600000, "ipoExpectedDate": "2024-01-26", "prevName": "Psyence Therapeutics Corp.", "nameChangeDate": "2026-02-21", "regularMarketChangePercent": -4.4379063, "regularMarketPrice": 2.5, "cryptoTradeable": false, "fiftyTwoWeekLowChange": 0.01999998, "fiftyTwoWeekLowChangePercent": 0.008064508, "fiftyTwoWeekRange": "2.48 - 468.35938", "fiftyTwoWeekHighChange": -465.85938, "fiftyTwoWeekHighChangePercent": -0.9946622, "fiftyTwoWeekChangePercent": -99.27294, "shortName": "Psyence Biomedical Ltd.", "longName": "Psyence Biomedical Ltd.", "epsTrailingTwelveMonths": -389.98, "corporateActions": [{"header": "Delisting", "message": "PBM was delisted effective Jan. 23, 2026", "meta": {"eventType": "DELISTING", "dateEpochMs": 1769144400000}}], "postMarketTime": 1771635595, "regularMarketTime": 1771621200, "exchange": "NCM", "messageBoardId": "finmb_698500412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "displayName": "Psyence Biomedical", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]